Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of MT-1207 in mild to moderate essential hypertension
ChiCTR2200060328Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MT-1207 in essential hypertension (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Change from baseline in mean sitting systolic blood pressure. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
MT-1207
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2200060328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060328.